Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, Canada, and internationally. The company’s products and services are used by healthcare providers in approximately 100 countries to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions, and the company has a direct presence, through the operation of commercial subsidiaries, in 25 countries. Divisions The company organizes its business into four divisions: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. Bioscience The Bioscience division includes activities relating to the manufacture of plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation and purification of plasma, and the sale and distribution of end products. The main plasma products the company manufactures are IVIG, Factor VIII, A1PI and albumin. The company also manufactures intramuscular (hyperimmune) immunoglobulins, ATIII, Factor IX and plasma thromboplastin component, or PTC. Diagnostic The Diagnostic division focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, including analytical instruments and reagents for diagnostics, as well as blood bank products. The company concentrates its Diagnostic business in immunohematology and hemostasis product lines. The Diagnostic division’s main customers are blood donation centers, clinical analysis laboratories and hospital immunohematology services. The Novartis Diagnostic Business the company acquired in January 2014 produces a complete line of products and systems to perform blood donor screening molecular tests aimed at detecting the pathogenic agents of transfusion related infectious diseases such as HIV, hepatitis B, hepatitis C, and West Nile Virus. Hospital The Hospital division manufactures and in certain instances installs products used by and in hospitals, such as parenteral solutions and enteral and parenteral nutritional fluids, which are sold almost exclusively in Spain and Portugal. It also includes products that the company does not manufacture but that the company markets as supplementary to products the company does manufacture. Raw Materials and Others The Raw Materials and Others division is involved in the sale of intermediate pastes and plasma products, as well as provision of engineering services to external companies. Geographic Markets The company operates in approximately 100 countries through distributors and subsidiaries in 25 countries. In the Asia-Pacific region, the company has established a presence through its subsidiaries and representative offices in Malaysia, China, Thailand, Singapore, Australia and Japan. Sales to Eastern Europe, the Middle East and Japan are made mostly by third parties outside of its sales network. The company’s sales in Latin America are made mainly by its sales network. Patents and Trademarks As of December 31, 2013, the company owned approximately 1,300 patents and patent applications, of which 459 are in the process of final approval. As of December 31, 2013, the company also owned approximately 2,100 trademarks, of which 86 are in the process of final approval. Research and Development The company’s research and development expenses included €123.3 million in 2013. Significant Events In June 2014, Grifols celebrated the opening of its new North Fractionation Facility (NFF) in Clayton, NC, where production capacity of plasma will almost double to approximately 6 million liters annually. Grifols' products are used to treat rare, chronic diseases such as a neurological disorder, immune deficiencies, hemophilia and genetic emphysema. History Grifols, S.A. was founded in 1940.
grifols sa (GRF:Continuous)
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Vallès
Phone: 34 935 71 22 00
Fax: 34 935 71 02 67www.grifols.com
|Endo International PLC||$66.92 USD||+0.63|
|Hikma Pharmaceuticals PLC||1,895 GBp||+26.00|
|Hospira Inc||$53.70 USD||-0.54|
|Stada Arzneimittel AG||€30.68 EUR||+0.257|
|UCB SA||€64.39 EUR||-1.03|
|View Industry Companies|
Sponsored Financial Commentaries
To contact GRIFOLS SA, please visit www.grifols.com. Company data is provided by Capital IQ. Please use this form to report any data issues.